Browse by author
Lookup NU author(s): Professor Ruth Plummer,
Professor Alan Calvert
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Purpose: The primary objectives of this study were to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of ZK 304709, a novel multi-targeted growth inhibitor (MTGI™), in man. Secondary end-points included safety evaluation, tolerability, pharmacokinetic profiling and assessment of response using standard and novel surrogate pharmacodynamic end-points. Materials and methods: Patients (n = 40) with advanced solid malignancies were treated with ZK 304709, administered orally once daily for 7 d with 14 d recovery. Doses were escalated in sequential cohorts of three patients with expansion to 6-7 patients should a dose-limiting toxicity occur. Results: ZK 304709 was safely administered up to 360 mg. However, above 90 mg blood concentrations increased only slightly. As this dose was not deemed likely to result in meaningful pharmacologic or clinical activity, the trial was stopped before the MTD was ascertained. It was therefore not possible to make a reliable assessment of efficacy or pharmacodynamic end-points. Conclusions: Due to the lack of further increment in blood concentrations above a dose of 90 mg, which was felt from previous animal studies to be unlikely to result in meaningful pharmacologic or clinical activity, this study was stopped early. © 2008 Elsevier Ltd. All rights reserved.
Author(s): Graham JS, Plummer R, McCoy C, Kowal K, Wiesinger H, Detjen K, Calvert AH, Wiedenmann B, Cassidy J
Publication type: Article
Publication status: Published
Journal: European Journal of Cancer
ISSN (print): 0959-8049
ISSN (electronic): 1879-0852
Altmetrics provided by Altmetric